Cite

    Floyd, J. et al. (n.d.). Case–control study of second‐line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. Diabetes, obesity & metabolism. 17 (12), pp. 1194-1197. [Online].